Drugs Made in America Acquisition (NASDAQ:DMAAU) Trading Down 0.5% – Time to Sell?

Drugs Made in America Acquisition Corp. (NASDAQ:DMAAU)’s share price fell 0.5% during mid-day trading on Wednesday . The stock traded as low as $10.50 and last traded at $10.50. 100 shares were traded during trading, a decline of 99% from the average session volume of 9,929 shares. The stock had previously closed at $10.55.

Drugs Made in America Acquisition Stock Down 0.5%

The firm has a fifty day moving average of $10.53 and a 200 day moving average of $10.51.

Drugs Made in America Acquisition Company Profile

Drugs Made in America Acquisition Corp is a special purpose acquisition company incorporated in Delaware and traded on the NASDAQ under the ticker DMAAU. It was organized to raise capital through its initial public offering and to identify and complete a business combination with one or more U.S.-based pharmaceutical or biotechnology companies.

The company’s investment mandate is focused on target businesses engaged in the development, manufacture or commercialization of finished dosage pharmaceuticals, active pharmaceutical ingredients and related medical products for the American market.